

```
=> b caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          0.21      0.21
```

FILE 'CAPLUS' ENTERED AT 15:12:35 ON 16 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25
 FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> s cyclodextrin and bacteria? and (infect? or invasi? or disease) and py<=2002
    37014 CYCLODEXTRIN
    10631 CYCLODEXTRINS
    38025 CYCLODEXTRIN
        (CYCLODEXTRIN OR CYCLODEXTRINS)
    530550 BACTERIA?
    467197 INFECT?
    70472 INVASI?
    1068513 DISEASE
    289951 DISEASES
    1196975 DISEASE
        (DISEASE OR DISEASES)
    22930220 PY<=2002
L1      44 CYCLODEXTRIN AND BACTERIA? AND (INFECT? OR INVASI? OR DISEASE)
        AND PY<=2002
```

```
=> l1 and hydroxypropyl
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s l1 and hydroxypropyl
    48892 HYDROXYPROPYL
    1 HYDROXYPROPYLS
    48892 HYDROXYPROPYL
        (HYDROXYPROPYL OR HYDROXYPROPYLS)
L2      8 L1 AND HYDROXYPROPYL
```

```

=> s l2 and listeri?
      10768 LISTERI?
L3      1 L2 AND LISTERI?

=> d l3 scan

L3      1 ANSWERS    CAPLUS    COPYRIGHT 2008 ACS on STN
IC      ICM  A61K031-00
CC      1-6 (Pharmacology)
      Section cross-reference(s): 10, 63
TI      Incensole and furanogermacrems and compounds in treatment for inhibiting
      neoplastic lesions and microorganisms
ST      neoplastic lesion treatment incensole furanogermacren compd; antitumor
      incensole furanogermacren; antimicrobial incensole furanogermacren
IT      Proteins
      RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
      THU (Therapeutic use); BIOL (Biological study); USES (Uses)
      (A, immunomodulator based on, pharmaceutical formulation further
      including; incensole and furanogermacrems and compds. as antitumor and
      antimicrobial agents)
IT      Lymphoma
      (B-cell; incensole and furanogermacrems and compds. as antitumor and
      antimicrobial agents)
IT      Fusion proteins (chimeric proteins)
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (BCR-ABL, antagonists, pharmaceutical formulation further including;
      incensole and furanogermacrems and compds. as antitumor and
      antimicrobial agents)
IT      Inflammation
      (Crohn's disease, treatment of; incensole and
      furanogermacrems and compds. as antitumor and antimicrobial agents)
IT      Intestine, disease
      (Crohn's, treatment of; incensole and furanogermacrems and compds. as
      antitumor and antimicrobial agents)
IT      Canarypox virus
      (IL-2 of, pharmaceutical formulation further including; incensole and
      furanogermacrems and compds. as antitumor and antimicrobial agents)
IT      GTPase-activating protein
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (RasGAP, inhibitors, pharmaceutical formulation further including;
      incensole and furanogermacrems and compds. as antitumor and
      antimicrobial agents)
IT      Proteins
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
      (Sdi 1, mimetics, pharmaceutical formulation further including;
      incensole and furanogermacrems and compds. as antitumor and
      antimicrobial agents)
IT      Skin, neoplasm
      (Sezary syndrome; incensole and furanogermacrems and compds. as
      antitumor and antimicrobial agents)
IT      Lymphoma
      (T-cell; incensole and furanogermacrems and compds. as antitumor and
      antimicrobial agents)
IT      Transcription factors
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)

```

(WT1 (Wilms' tumor suppressor 1), therapy based on; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Keratosis
(actinic; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lung, neoplasm
(adenocarcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Melanoma
(amelanotic; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Urokinase-type plasminogen activator receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-dorsalizing morphogenetic protein-1, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antitumor agents
(antineoplastons, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Nutrients
(antinutrients, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug resistance
(antitumor; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lung, disease
(aspergillosis, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Infection
(bacterial, intracellular or extracellular, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-Raf, antagonists, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Mycosis
(candidiasis, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Prostate gland, neoplasm
(carcinoma, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Ovary, neoplasm
Stomach, neoplasm
(carcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Mycobacterium
(cell wall sk and monophosphoryl lipid A, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as

antitumor and antimicrobial agents)

IT Diterpenes
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cembranoid, alcs.; incensole and furanogermacrems and compds. as
 antitumor and antimicrobial agents)

IT Diterpenes
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cembranoid; incensole and furanogermacrems and compds. as antitumor
 and antimicrobial agents)

IT Uterus, disease
 (cervix, dysplasia; incensole and furanogermacrems and compds. as
 antitumor and antimicrobial agents)

IT Uterus, neoplasm
 (cervix; incensole and furanogermacrems and compds. as antitumor and
 antimicrobial agents)

IT Porphyrins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (chlorins, benzo-, pharmaceutical formulation further including;
 incensole and furanogermacrems and compds. as antitumor and
 antimicrobial agents)

IT Porphyrins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (chlorins, pharmaceutical formulation further including; incensole and
 furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Polymers, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (co-, enteric coating of; incensole and furanogermacrems and compds. as
 antitumor and antimicrobial agents)

IT Intestine, neoplasm
 (colon, carcinoma; incensole and furanogermacrems and compds. as
 antitumor and antimicrobial agents)

IT Intestine, neoplasm
 (colon, polyp; incensole and furanogermacrems and compds. as antitumor
 and antimicrobial agents)

IT Intestine
 (colon, precancerous lesion in; incensole and furanogermacrems and
 compds. as antitumor and antimicrobial agents)

IT Carcinoma
 Intestine, neoplasm
 (colon; incensole and furanogermacrems and compds. as antitumor and
 antimicrobial agents)

IT Polyoxyalkylenes, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (conjugates with pyridoxylated Hb; incensole and furanogermacrems and
 compds. as antitumor and antimicrobial agents)

IT Quinones
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cyclopentantraquinones, pharmaceutical formulation further including;
 incensole and furanogermacrems and compds. as antitumor and
 antimicrobial agents)

IT Stem cell
 (division inhibitors, pharmaceutical formulation further including;

incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Carbohydrates, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug delivery systems containing; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antibodies and Immunoglobulins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug targeting to HIV infected cells using; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Tumor antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (drug targeting with monoclonal antibody to; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Bronchi, disease
 Prostate gland, disease
 (dysplasia; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Skin, neoplasm
 (dysplastic nevus syndrome; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Dendritic cell
 (enhancement of endogenous precursor; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (enhancement of endogenous; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Polymers, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enteric coating of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (enteric-coated; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (enteric; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
 (enterohemorrhagic, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
 (enteroinvasive, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
 (enteropathogenic, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
 (enterotoxigenic, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lung, neoplasm
 (epidermoid; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Gene therapy

(erythrocyte, vector system, pharmaceutical formulation further including; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (for apoptosis, modulators of, pharmaceutical formulation further including; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Carcinoma
 (gastric; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Multidrug resistance
 (gene inhibitor, pharmaceutical formulation further including; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Apoptosis
 (gene modulators or regulators, pharmaceutical formulation further including; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Erythrocyte
 (gene therapy vector system, pharmaceutical formulation further including; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Envelope proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gp120env, drug targeting to HIV infected cells using antibodies to; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Envelope proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gp160env, drug targeting to HIV infected cells using antibodies to; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Peptides, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (immunostimulant, pharmaceutical formulation further including; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Chemotherapy
 Parasitocides
 Radiotherapy
 Surgery
 (in combination with; incensole and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Adrenal gland, neoplasm
 Anti-AIDS agents
 Anti-infective agents
 Antiarthritics
 Antiasthmatics
 Antidiabetic agents
 Antidiarrheals
 Antitumor agents
 B-cell leukemia
 Bladder, neoplasm
 Brain, neoplasm
 Burn
 Central nervous system, neoplasm

Drug delivery systems
 Enterococcus faecalis
 Hairy cell leukemia
 Hematopoietic neoplasm
 Hodgkin's disease
 Human
 Leukemia
 Leukemia
 Lymphoma
 Mammary gland, neoplasm
 Melanoma
 Monocytic leukemia
 Mouth, neoplasm
 Multiple myeloma
 Myeloid leukemia
 Myelomonocytic leukemia
 Neoplasm
 Newborn
 Ovary, neoplasm
 Pancreas, neoplasm
 Prostate gland, neoplasm
 Sarcoma
 Staphylococcus aureus
 Stomach, neoplasm
 T-cell leukemia
 Testis, neoplasm
 (incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Polyoxyalkylenes, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Yeast
 (infection with, treatment of immunodysregulation condition caused by; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Intestine, disease
 (inflammatory, treatment of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Cartilage
 (inhibitor derived from, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Stem cell
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Insulin-like growth factor I receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Translation, genetic
 (inhibitors of, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
 IT Signal transduction, biological
 (inhibitors or modulators, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Macrophage migration inhibitory factor
Ras proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, pharmaceutical formulation further including; incensole
and furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Insulin-like growth factor-binding proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(insulin-like growth factor I-binding, pharmaceutical formulation
further including; incensole and furanogermacrene and compounds. as
antitumor and antimicrobial agents)

IT Parasite
(intracellular or extracellular infection with, treatment of
immunodysregulation condition caused by; incensole and furanogermacrene
and compounds. as antitumor and antimicrobial agents)

IT Intestine, disease
(irritable bowel syndrome, treatment of; incensole and furanogermacrene
and compounds. as antitumor and antimicrobial agents)

IT Digestive tract
(irritation, treatment of immunodysregulation condition caused by;
incensole and furanogermacrene and compounds. as antitumor and
antimicrobial agents)

IT Paracoccidioides
(juvenile paracoccidioidomycosis, treatment of immunodysregulation
condition caused by; incensole and furanogermacrene and compounds. as
antitumor and antimicrobial agents)

IT Lung, neoplasm
(large-cell carcinoma; incensole and furanogermacrene and compounds. as
antitumor and antimicrobial agents)

IT Bladder, disease
Skin, disease
(lesions; incensole and furanogermacrene and compounds. as antitumor and
antimicrobial agents)

IT Virus
(lipid envelope, treatment of immunodysregulation condition caused by
infection with; incensole and furanogermacrene and compounds. as
antitumor and antimicrobial agents)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(lipophilic disaccharide, pharmaceutical formulation further including;
incensole and furanogermacrene and compounds. as antitumor and
antimicrobial agents)

IT Drug delivery systems
(liposomes; incensole and furanogermacrene and compounds. as antitumor and
antimicrobial agents)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(lytic, pharmaceutical formulation further including; incensole and
furanogermacrene and compounds. as antitumor and antimicrobial agents)

IT Pulverization
(micronization; incensole and furanogermacrene and compounds. as antitumor
and antimicrobial agents)

IT Double stranded RNA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(mismatched, pharmaceutical formulation further including; incensole

and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monoclonal, conjugates, with liposome or carbohydrate vehicles, to tumor-associated antigen; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Antibodies and Immunoglobulins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monoclonal, to human chorionic gonadotropin, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Lipid A
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monophosphates, and mycobacterium cell wall sk, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Nerve, disease
 (motor, treatment of; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Gram-positive bacteria
 (multi-drug resistant; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Gene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (multidrug resistance, inhibitor, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (nasal; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Nerve, neoplasm
 (neuroblastoma; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Antioxidants
 (nitroxide, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Lymphocyte
 (null cell, leukemia; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Interleukin 2
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of canarypox virus, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Cytokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (oral inducer, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (oral; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (ovarian; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (parenterals; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antiviral agents
 (pharmaceutical formulation further containing; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulation further containing; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Angiogenesis inhibitors
 Antiandrogens
 Antiestrogens
 Antivenoms
 Cytotoxic agents
 Immunostimulants
 Mycobacterium bovis
 Venoms
 (pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antisense oligonucleotides
 Estrogens
 Hormones, animal, biological studies
 Interleukins
 Leukemia inhibitory factor
 Neuregulin 1
 Oligonucleotides
 Polyamines
 Ribozymes
 Steroids, biological studies
 Taxanes
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Disease, animal
 (polyposis syndrome; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Fatty acids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (poppy seed-oil, Et esters, labeled with iodine-131, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Central nervous system, disease
 Kidney, disease
 Lung, disease
 Mammary gland, disease
 Stomach, disease
 (precancerous lesion in; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (prodrugs; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (prostatic, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (pulmonary adenocarcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (pulmonary large-cell; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (pulmonary small-cell; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Hemoglobins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (reaction products, with pyridoxal phosphate, conjugates with polyoxyethylene, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (rectal; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Kidney, neoplasm
 (renal cell carcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (renal cell; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antitumor agents
 (resistance to; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Ribosome-inactivating proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (saporin, fibroblast growth factor conjugates; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (senescence-derived inhibitor 1, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Oligonucleotides
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sense, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Shock (circulatory collapse)
 (septic, treatment of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (single chain antigen binding protein, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Cell wall
 (sk of mycobacteria and monophosphoryl lipid A, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Leukemia

(small cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Lung, neoplasm
(small-cell carcinoma; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Neoplasm
(solid; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Carcinoma
(squamous cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(sublingual; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Glycosaminoglycans, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Lupus erythematosus
(systemic, treatment of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Human immunodeficiency virus
(targeting to cells infected with; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thymopoietin, agonists, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(topical; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Stem cell factor
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(totipotent, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Adeno-associated virus
Balantidium
Balantidium coli
Borrelia
Campylobacter
Candida
Coronavirus
Cryptococcus (fungus)
Cryptosporidium
DNA viruses
Entamoeba
Entamoeba histolytica
Filovirus
Flavivirus
Haemophilus
Hantavirus
Human papillomavirus
Human parainfluenza virus
Human poliovirus
Influenza virus

Legionella
Leishmania
Leishmania braziliensis
Leishmania donovani
Leishmania mexicana
Leishmania tropica

Listeria

Measles virus
Mycoplasma
Papillomavirus
Pestivirus
Picornaviridae
Plasmodium berghei
Plasmodium falciparum
Plasmodium malariae
Plasmodium ovale
Plasmodium vivax
Pneumocystis
Pneumocystis carinii
Poxviridae
Pseudomonas
RNA viruses
Respiratory syncytial virus
Retroviridae
Rhinovirus
Rubivirus
Salmonella
Shigella
Staphylococcus
Streptococcus
Togaviridae
Toxoplasma
Toxoplasma gondii
Trichomonas
Trichomonas vaginalis
Trypanosoma
Trypanosoma brucei
Trypanosoma cruzi
Trypanosoma gambiense
Trypanosoma rhodesiense
Vibrio
Yersinia

(treatment of immunodysregulation condition caused by infection
with; incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT Gamma ray

(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT Corticosteroids, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT Nucleoside analogs

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(treatment of immunodysregulation condition caused by treatment with;

incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Immunosuppressants

Mycosis

Protozoa

Wound

(treatment of immunodysregulation condition caused by; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Arthritis

Asthma

Autoimmune disease

Cachexia

Cirrhosis

Diabetes mellitus

Diarrhea

Immune disease

Multiple sclerosis

Respiratory distress syndrome

(treatment of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Cytotoxic agents

(tyrphostins, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems

(vaginal; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Infection

(viral, treatment of immunodysregulation condition caused by; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Disease, animal

(wasting, treatment of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Interferons

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α , n1, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Interferons

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α , n3, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Interferons

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α , pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Interferons

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α -2a, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Interferons

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α -2b, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Lactams

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (β -, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (β 1, a, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (γ , 1b, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 37221-79-7, Vasoactive intestinal peptide
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antagonist, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 9002-06-6, Thymidine kinase
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antagonists, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 505-60-2, Mustard
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anticancer, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 7585-39-9, β - Cyclodextrin 7585-39-9D, β - Cyclodextrin, hydroxypropyl derivs. 10016-20-3, α - Cyclodextrin 12619-70-4, Cyclodextrin 17465-86-0, γ - Cyclodextrin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as pharmaceutical carrier; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 80-62-6, Methyl methacrylate 2867-47-2, (2-Dimethylaminoethyl) methacrylate 9004-38-0, Cellulose acetate phthalate 34346-01-5, Poly(lactic acid-glycolic acid) 441015-98-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enteric coating of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 121749-39-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (epharmaeputical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 54-47-7D, Pyridoxal phosphate, reaction products with Hb conjugates
 76-49-3, Bornyl acetate 80-57-9, Verbenone 87-44-5, β -Caryophyllene 88-84-6, β -Guaiene 99-49-0, Carvone 99-83-2, α -Phellandrene 99-87-6, p-Cymene 112-14-1, Octyl acetate 123-35-3, Myrcene 473-11-0, Eudesmane 489-80-5, Guaiane 495-61-4, β -Bisabolene 502-61-4, Farnesene 507-70-0, Borneol 511-59-1, β -Santalene 512-61-8, α -Santalene 515-12-8, Elemene 523-47-7, β -Cadinene 555-10-2, β -Phellandrene 562-74-3, Terpinen-4-ol 1335-14-4 1674-08-4, trans-Pinocarveol 1820-09-3, trans-Verbenol 2867-05-2, α -Thujene 3856-25-5, α -Copaene 4602-84-0, Farnesol 5208-59-3, β -Bourbonene

6753-98-6, Humulene 6895-56-3, β -Bergamotene 7663-66-3, Bergamotane 8007-35-0, Terpinyl acetate 8013-00-1, Terpinene 10178-38-8, Echinodol 14998-63-1D, Rhenium-186, etidronate complexes, biological studies 17627-44-0, α -Bisabolene 18794-84-8, β -Farnesene 19912-61-9, Furanodiene 20479-06-5, β -Ylangene 21698-66-8, Incensole oxide 21698-67-9, Incensole oxide acetate 22419-74-5, Incensole 25269-16-3, Isocembrene 25322-68-3D, conjugates with pyridoxylated Hb 28028-64-0, Germacrene 29063-28-3, Octanol 29350-73-0, Cadinene 31570-39-5, Cembrene-A 34701-53-6 35731-88-5, Isoincensole oxide 67921-02-2, Cembrenol 94325-73-2 94325-73-2D, compds. 122537-31-9, Oplopane 441771-56-8, Isoincensole 441771-57-9, Isoincensole acetate 441771-74-0, SKB 4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 141436-78-4, Protein kinase C

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitor, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 52660-18-1, Casein kinase 1 366806-33-9, Casein kinase 2

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors (ICOS), pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 144114-21-6, HIV-1 Protease

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors, pharmaceutical formulation further containing; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 70-18-8, Glutathione, biological studies 9030-21-1, Purine nucleoside

phosphorylase 9040-48-6, Gelatinase 79747-53-8, Protein tyrosine

phosphatase 79955-99-0, Stromelysin 80449-02-1, Tyrosine kinase

106096-93-9, Basic fibroblast growth factor 120178-12-3, Telomerase

131384-38-8, Ras farnesyltransferase 140879-24-9, Proteasome

141256-52-2, Matrilysin 141907-41-7, Matrix metalloproteinase

375798-61-1, Phosphatase, phosphoprotein

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 10102-43-9, Nitric oxide, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(modulators, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 9002-61-3, Chorionic gonadotropin

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(monoclonal antibody to human, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 9068-38-6, Reverse transcriptase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(nonnucleoside inhibitors of, pharmaceutical formulation further containing; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 1406-18-4, Vitamin E

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oil, as pharmaceutical carrier; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 54-05-7, Chloroquine 54-42-2, Idoxuridine 60-54-8, Tetracycline

69-74-9, Cytarabine Hydrochloride 70-00-8, Trifluridine 80-08-0, Dapsone 90-34-6, Primaquine 100-33-4, Pentamidine 130-95-0, Quinine 443-48-1, Metronidazole 494-79-1, Melarsoprol 665-66-7, Amantadine Hydrochloride 1501-84-4, Rimantadine Hydrochloride 1910-68-5, Methisazone 3056-17-5, d4T 3736-81-0, Diloxanide furoate 5536-17-4, Vidarabine 7481-89-2, DdC 8064-90-2 9004-70-0, HE-2000 10500-82-0, Famotidine Hydrochloride 10540-97-3, Memotidine Hydrochloride 11006-77-2, Statolon 15176-29-1, Edoxudine 15185-43-0, DOTC 19387-91-8, Tinidazole 19885-51-9, Aranotin 22994-85-0, Benznidazole 23256-30-6, Nifurtimox 25526-93-6, Alovudine 27591-69-1, Tilorone Hydrochloride 27762-78-3, Kethoxal 29984-33-6, Vidarabine Phosphate 30516-87-1, AZT 35607-20-6, Avridine 36791-04-5, Ribavirin 36983-81-0, Fosfonet Sodium 37338-39-9 39809-25-1, Penciclovir 51867-87-9 53230-10-7, Mefloquine 56219-57-9, Arildone 59277-89-3, Acyclovir 63198-97-0, Viroxime 63585-09-1, Foscarnet Sodium 63968-64-9D, Artemisinin, derivs. 68693-30-1, Somantadine Hydrochloride 69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69655-05-6, DdI 69657-51-8, Acyclovir Sodium 69756-53-2, Halofantrine 72301-78-1, Zinviroxime 72301-79-2, Enviroxime 73514-87-1, Fosarilate 77181-69-2, Sorivudine 80883-55-2, Enviradene 82410-32-0, Ganciclovir 84408-37-7, Desciclovir 85087-20-3, Doxycycline 87495-31-6, Disoxaril 95233-18-4, Atovaquone 100817-46-7, Stibogluconic acid 104227-87-4, Famciclovir 106362-32-7, Peptide T 106941-25-7, PME A 107910-75-8, Ganciclovir Sodium 110042-95-0, Acemannan 110143-10-7, Lodenosine 113852-37-2, Cidofovir 124436-59-5, Pirodavis 124832-27-5, Valacyclovir Hydrochloride 127759-89-1, Lobucavir 127779-20-8, Saquinavir 129618-40-2, Nevirapine 132210-43-6, Cipamfylline 134678-17-4, 3TC 136470-78-5, Abacavir 136817-59-9, Delavirdine 137487-62-8, Alvircept Sudotox 138540-32-6, Ateviridine Mesylate 141204-94-6, Co-artemether 142340-99-6 142632-32-4, Calanolide A 143491-57-0, Coviracil 145514-04-1, DAPD 147127-20-6, Tenofovir 147221-93-0, Delavirdine Mesylate 147318-81-8, KNI-272 147362-57-0, Loviride 149845-06-7, Saquinavir Mesylate 149950-60-7, Emivirine 150378-17-9, Indinavir 153127-49-2, ALX40-4C 154598-52-4, DMP 266 155148-31-5, AMD 3100 155213-67-5, Ritonavir 156879-70-8 159519-65-0, Pentafuside 159989-64-7, Nelfinavir 163451-80-7 170020-61-8, FP-21399 174484-41-4, Tipranavir 177932-89-7, DMP-450 178979-85-6, AG 1549 185220-03-5, PNU142721 192725-17-0, ABT-378 214287-88-4, DPC961 216863-66-0, L-756423 251562-00-2, T-1249 383198-56-9, BW 141 383198-57-0, BMS-232630 383198-58-1, PRO 542

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further containing; incense and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 50-07-7, Mutamycin 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepe 53-19-0, Mitotane 53-43-0, DHEA 53-79-2, Puromycin 54-71-7, Pilocarpine hydrochloride 54-91-1, Pipobroman 55-21-0D, Benzamide, N-substituted compds. 55-86-7, Mechlorethamine Hydrochloride 55-86-7D, Nitrogen mustard, derivs. 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl oestradiol 57-83-0, Progesterone, biological studies 58-05-9, Leucovorin 58-58-2, Puromycin Hydrochloride 59-05-2, Methotrexate 66-75-1, Uracil Mustard 83-89-6, Acriquine 101-60-0, Porphyrin 106-60-5, Aminolevulinic acid 114-70-5, Sodium phenylacetate 122-79-2, Phenylacetate 125-45-1, Azetepa 125-84-8, Aminogluthetamide 127-07-1, Hydroxyurea 143-67-9, Vinblastine Sulfate 145-63-1, Suramin 147-94-4, Cytarabine 148-82-3,

Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 302-49-8,
 Uredepa 302-79-4, Tretinoin 305-03-3, Chlorambucil 320-67-2,
 Azacitidine 359-83-1, Pentazocine 364-62-5, Metoclopramide 366-70-1,
 Procarbazine Hydrochloride 378-44-9, Betamethasone 423-55-2,
 Perflubron 459-86-9, Mitoguazone 465-65-6, Naloxone 472-15-1,
 Betulinic acid 481-29-8, Epiandrosterone 518-28-5, Podophyllotoxin
 520-85-4, Medroxyprogesterone 521-12-0, Dromostanolone Propionate
 536-59-4, Perillyl alcohol 548-04-9, Hypericin 566-48-3, Formestane
 569-57-3, Chlorotrianisene 578-95-0D, Acridone, imidazo derivs.
 578-95-0D, Acridone, propylbis derivs. 595-33-5, Megestrol Acetate
 645-05-6, Altretamine 646-08-2, β -Alethine 671-16-9, Procarbazine
 801-52-5, Porfiromycin 865-21-4, Vinblastine 911-45-5, Clomifene
 968-93-4, Testolactone 1271-19-8, Titanocene dichloride 1402-81-9,
 Ambomycin 1403-99-2, Mitogillin 1404-00-8, Mitomycin 1404-15-5,
 Nogalamycin 1404-20-2, Peliomycin 1404-64-4, Sparsomycin 1661-29-6,
 Meturedopa 1972-08-3, Dronabinol 1980-45-6, Benzodepa 2068-78-2,
 Vincristine Sulfate 2353-33-5, Decitabine 2508-89-6 2608-24-4,
 Pipsulfan 2809-21-4D, Etidronic acid, rhenium-186 complexes
 2919-66-6, Melengestrol acetate 2998-57-4, Estramustine 2998-57-4D,
 Estramustine, analogs 3073-59-4, Hexamethylene bisacetamide 3094-09-5,
 Doxifluridine 3562-63-8, Megestrol 3778-73-2, Ifosfamide 3930-19-6,
 Streptonigrin 4105-38-8 4291-63-8, Cladribine 4342-03-4, Dacarbazine
 4342-07-8 4803-27-4, Anthramycin 5072-26-4, Buthionine sulfoximine
 5373-42-2, Thaliblastine 5508-58-7, Andrographolide 5579-27-1,
 Simtrazene 5581-52-2, Thiamiprine 5696-17-3, Epipropidine 6157-87-5,
 Trestolone Acetate 7281-31-4, Vinglycinatate Sulfate 7440-06-4D,
 Platinum, lipophilic compds. or complexes 7440-06-4D, Platinum, triamine
 complexes 7644-67-9, Azotomycin 7689-03-4D, Camptothecin, derivs.
 7724-76-7, Riboprime 7761-45-7, Metoprime 8052-16-2, Cactinomycin
 9002-71-5, Thyroid-stimulating hormone 9014-02-2, Zinostatin
 9014-42-0, Thrombopoietin 9014-42-0D, Thrombopoietin, mimetics
 9015-68-3, Asparaginase 9027-98-9 9041-93-4, Bleomycin Sulfate
 9050-67-3, Sizofiran 10043-49-9, Gold-198, biological studies
 10087-89-5, Enpromate 10318-26-0, Mitolactol 10403-51-7, Mitindomide
 10540-29-1, Tamoxifen 11002-22-5, Apurinic acid 11029-06-4, Elemene
 11043-98-4, Mitocromin 11043-99-5, Mitomalcin 11056-06-7, Bleomycin
 11056-12-5, Cirolemycin 11056-14-7, Mitocarcin 11056-15-8, Mitosper
 12713-07-4D, Verdin, compds. 13010-47-4, Lomustine 13311-84-7,
 Flutamide 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol
 13909-09-6, Semustine 14769-73-4, Levamisole 15475-56-6, Methotrexate
 Sodium 15639-50-6, Safingol 15663-27-1, Cisplatin 17021-26-0,
 Calusterone 17902-23-7, Tegafur 18378-89-7, Plicamycin 18416-85-8,
 Lombricine 18556-44-0, Vinrosidine Sulfate 18588-57-3, Etoprine
 18883-66-4, Streptozocin 19916-73-5, O6-Benzylguanine 20098-14-0,
 Idramantone 20537-88-6, Amifostine 20638-84-0, Retinamide
 20830-81-3, Daunorubicin 21059-48-3, Veramine 21679-14-1, Fludarabine
 22668-01-5, Etanidazole 23214-92-8, Doxorubicin 23541-50-6,
 Daunorubicin Hydrochloride 23593-75-1, Clotrimazole 24280-93-1,
 Mycophenolic Acid 24584-09-6, Dexrazoxane 25316-40-9, Adriamycin
 27302-90-5, Oxisuran 27314-97-2, Tirapazamine 27548-93-2D, Baccatin
 III, derivs. 27686-84-6, Masoprocol 29069-24-7, Prednimustine
 29767-20-2, Teniposide 30303-65-2, Docosanol 30387-51-0, Asperlin
 30868-30-5, Pyrazofurin 31430-18-9, Nocodazole 31441-78-8,
 Mercaptopurine 32954-58-8, Ipomeanol 33069-62-4, Paclitaxel
 33069-62-4D, Paclitaxel, analogs and derivs. 33419-42-0, Etoposide
 35301-24-7, Cedefingol 35846-53-8, Maytansine 35943-35-2, Triciribine
 36508-71-1, Zorubicin Hydrochloride 37717-21-8, Flurocitabine
 38270-90-5, Strontium Chloride Sr 89 38321-02-7, Dexverapamil

39325-01-4, Picibanil 40391-99-9, Pamidronic acid 41575-94-4, Carboplatin 41729-52-6, Dezaguanine 41992-22-7, Spirogermanium Hydrochloride 42228-92-2, Acivicin 42616-25-1, Methioninase 50264-69-2, Lonidamine 51264-14-3, Amsacrine 51321-79-0, Sparfosic acid 52128-35-5, Trimetrexate 52205-73-9, Estramustine Phosphate Sodium 52794-97-5, Carubicin Hydrochloride 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54081-68-4, Vinleurosine Sulfate 54824-17-8, Mitonafide 55435-65-9, Acodazole Hydrochloride 56390-09-1, Epirubicin Hydrochloride 56420-45-2, Epirubicin 56605-16-4, Spiromustine 56741-95-8, Bropirimine 57381-26-7, Irsogladine 57576-44-0, Aclarubicin 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57852-57-0, Idamycin 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58525-82-9, Azatyrosine 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59653-73-5, Teroxirone 59917-39-4, Vindesine Sulfate 59989-18-3, 5-Ethynyluracil 60084-10-8, Tiazofurin 60203-57-8, Prostaglandin J2 60940-34-3, Ebselen 61825-94-3, Oxaliplatin 61966-08-3, Triciribine Phosphate 62304-98-7, Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62816-98-2, Ormaplatin 62928-11-4, Iproplatin 63590-19-2, Balanol 63612-50-0, Nilutamide 63950-06-1, Esorubicin Hydrochloride

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and

furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfosfate 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 65807-02-5, Goserelin 65886-71-7, Fazarabine 66569-27-5, Sparfosate Sodium 66849-34-1, Dexifosfamide 67699-41-6, Vinzolidine Sulfate 68278-23-9, Eflornithine Hydrochloride 68475-42-3, Anagrelide 69839-83-4, Didox 70052-12-9, Eflornithine 70384-29-1, Peplomycin Sulfate 70476-82-3, Mitoxantrone Hydrochloride 70641-51-9, Edelfosine 70711-40-9, Ametantrone Acetate 71294-60-5, Rohitukine 71439-68-4, Bisantrene Hydrochloride 71486-22-1, Vinorelbine 71522-58-2, Forfenimex 71628-96-1, Menogaril 72238-02-9D, Retelliptine, demethyl derivs. 72496-41-4, Pirarubicin 72629-69-7, Sarcophytol A 72732-56-0, Piritrexim 72741-87-8, Swainsonine 73105-03-0, Pentamustine 74149-70-5, Parabactin 74381-53-6, Leuprolide Acetate 74790-08-2, Spiroplatin 75219-46-4, Atrimustine 75330-75-5, Lovastatin 75607-67-9, Fludarabine Phosphate 75775-33-6D, Purpurin, compds. 75957-60-7, Splenopentin 76932-56-4, Nafarelin 77016-85-4, Plomestane 77327-05-0, Didemnin B 77599-17-8, Panomifene 77858-21-0, Velaresol 78113-36-7, Romurtide 78186-34-2, Bisantrene 79778-41-9, Neridronic acid 79831-76-8, Castanospermine 80451-05-4, Cecropin B 80576-83-6, Edatrexate 80663-95-2 80841-47-0, Asulacrine 81424-67-1, Caracemide 81965-43-7, SarCNU 82230-03-3, Carbetimer 82413-20-5, Droloxifene 82707-54-8, Neutral endopeptidase 82855-09-2D, Combretastatin, analogs 82952-64-5, Trimetrexate Glucuronate 83086-73-1, Tubulozole Hydrochloride 83150-76-9, Octreotide 83200-11-7, Vinepidine Sulfate 83519-04-4, Ilmofosine 83997-75-5, Iododoxorubicin 84030-84-2, Telluopyrylium 84088-42-6, Roquinimex 84371-65-3, Mifepristone 84412-94-2, Ruboxyl 85465-82-3, Thymotrinan 85622-93-1, Temozolomide 85754-59-2, Ambamustine 85969-07-9, Budotitane 85977-49-7, Tauromustine 86976-56-9, Betaclamycins 87005-03-6, Panaxytriol 87434-82-0, Dezaguanine Mesylate 87806-31-3, Porfimer Sodium 87810-56-8, Fostriecin 87860-39-7, Fostriecin Sodium 88303-60-0, Losoxantrone 88303-61-1, Losoxantrone Hydrochloride 89565-68-4, Tropisetron 89778-26-7, Toremifene 89778-27-8, Toremifene Citrate 90357-06-5, Bicalutamide 90996-54-6, Rhizoxin 92047-76-2,

Tetrachlorodecaoxide 92118-27-9, Fotemustine 92788-10-8, Rogletimide 92803-82-2, Aphidicolin glycinate 94079-80-8, Cicaprost 95058-81-4, Gemcitabine 95734-82-0, Nedaplatin 95933-72-5, Amidox 96201-88-6, Brequinar Sodium 96301-34-7, Atamestane 96346-61-1, Onapristone 96389-68-3, Crisnatol 96389-69-4, Crisnatol Mesylate 96392-96-0, Dexormaplatin 96892-57-8, Hepsulfam 97068-30-9, Elsamitrucin 97534-21-9, Merbarone 97682-44-5, Irinotecan 97752-20-0, Droloxifene Citrate 97919-22-7 98319-26-7, Finasteride 98383-18-7, Ecomustine 98631-95-9, Sobuzoxane 99009-20-8, Pyrazoloacridine 99011-02-6, Imiquimod 99283-10-0, Molgramostim 99614-02-5, Ondansetron 100286-90-6, Irinotecan Hydrochloride 100324-81-0, Lisofylline 102396-24-7, Jasplakinolide 102676-31-3, Fadrozole Hydrochloride 102676-47-1, Fadrozole 102822-56-0, Mannostatin A 103222-11-3, Vapreotide 103612-80-2 104493-13-2, Adecyphenol 105118-12-5, Piroxantrone Hydrochloride 105149-04-0, Osaterone 105615-58-5, Oxaunomycin 105844-41-5, Plasminogen activator inhibitor 106096-93-9D, Basic fibroblast growth factor, saporin conjugates 106400-81-1, Lometrexol 107000-34-0, Zanolterone 107256-99-5, Tamoxifen methiodide 107868-30-4, Exemestane 108736-35-2, Lanreotide 108852-90-0, Nemorubicin 109837-67-4, Cycloplatin 110267-81-7, Amrubicin 110311-27-8, Sulofenur 110314-48-2, Adozelesin 110690-43-2, Emitefur 110942-02-4, Aldesleukin 110942-08-0, Luprolide 111490-36-9, Zeniplatin 111523-41-2, Enloplatin 112515-43-2, Topsentin 112522-64-2, Acetyldinaline 112809-51-5, Letrozole 112859-71-9, Fluasterone 112887-68-0, Raltitrexed 112965-21-6, Calcipotriol 114084-78-5, Ibandronic acid 114285-68-6, Lentinan sulfate 114517-02-1, Fosquidone 114977-28-5, Taxotere 115150-59-9, Antagonist G 115308-98-0, Tallimustine 115566-02-4, Bistratene A 115575-11-6, Liarozole 115956-12-2, Dolasetron 116057-75-1, Idoxifene 117048-59-6, Combretastatin A4 117091-64-2, Etoposide Phosphate 118292-40-3, Tazarotene 119169-78-7, Epristeride 119413-54-6, Topotecan Hydrochloride 119813-10-4, Carzelesin 120287-85-6, Cetorelix 120408-07-3, Lometrexol Sodium 120500-15-4, Leinamycin 120511-73-1, Anastrozole 120685-11-2, Benzoylstauosporine 121181-53-1, Filgrastim 121263-19-2, Calphostin C 121288-39-9, Loxoribine 121547-04-4, Mirimostim 122111-03-9, Gemcitabine Hydrochloride 122341-38-2, Temoporfin 122431-96-3 122898-63-9, Phenazinomycin 123040-69-7, Azasetron 123258-84-4, Itasetron 123760-07-6, Zinostatin stimalamer 123774-72-1, Sargramostim 123830-79-5, Teloxantrone Hydrochloride 123948-87-8, Topotecan 124012-42-6, Galocitabine 124689-65-2D, Cryptophycin A, derivs. 124784-31-2, Erbulozole 124904-93-4, Ganirelix 125317-39-7, Vinorelbine Tartrate 125392-76-9, Acylfulvene 125533-88-2, Mofarotene 126297-39-0, Lissoclinamide 7 126443-96-7, Napavin 127984-74-1, Lanreotide Acetate 128505-88-4, Naphterpin 128768-09-2, Placetin A 128768-11-6, Placetin B 129497-78-5, Verteporfin 129564-92-7, Azatoxin 129655-21-6, Bizelesin 129731-10-8, Vorozole 130167-69-0, Pegaspargase 130288-24-3, Duocarmycin SA 130364-39-5, Rubiginone B1 130370-60-4, Batimastat 131190-63-1, Saintopin 132036-88-5, Ramosetron 132073-72-4, Tetrazomine 133432-71-0, Peldesine 134088-74-7, Nartograstim 134381-30-9, Conagenin 134523-84-5 134633-29-7, Tecogalan Sodium 134861-62-4, Dioxamycin 135257-45-3, Crambescidin 816 135381-77-0, Flezelastine 135383-02-7, Stipiamide 135558-11-1, Lobaplatin 135819-69-1 135968-09-1, Lenograstim 137018-54-3, Okicenone 137099-09-3, Turosteride 137219-37-5, Dehydrodidemnin B 137647-92-8, Axinastatin 1 137964-32-0 139755-79-6, Safingol Hydrochloride 140207-93-8, Pentosan polysulfate sodium 140703-49-7, Meterelin 142880-36-2, Ilomastat 144885-51-8, Sodium borocaptate

144916-42-7, Sonermin 145124-30-7, Bisnafide dimesylate 145858-50-0,
Liarozole Hydrochloride 146426-40-6, Flavopiridol 148317-76-4, Oracin
148584-53-6 148717-58-2, Palauamine 148717-90-2, Squalamine
149204-42-2, Kahalalide F

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 149260-80-0, Mycaperoxide B 149355-77-1, Lamellarin-N triacetate
149633-91-0, Leptolstatin 149715-96-8, Spongistatin 1 149882-10-0,
Lurtotecan 150829-93-9, Nisamycin 151272-78-5, Antarelix
152923-56-3, Dacliximab 153723-34-3, Axinastatin 2 153723-35-4,
Axinastatin 3 154039-60-8, Marimastat 154229-19-3, Abiraterone
154248-96-1, Iroplact 154277-21-1, Cypemycin 154361-50-9, Capecitabine
155233-30-0, Curacin A 156586-89-9, Edrecolomab 156790-85-1, Variolin
B 157078-48-3, Isohomohalichondrin B 157857-21-1, Maspin
158792-24-6, Collismycin A 158792-25-7, Collismycin B 168482-36-8,
Cryptophycin 8 172793-30-5 173046-02-1, Thiocoraline 174305-65-8,
Breflate 181887-82-1, Nitrullin 188364-40-1, CARN 700 200139-38-4,
Suradista 212894-59-2, Pentrozole 246252-04-0, Lutetium texaphyrin
246252-06-2, Gadolinium texaphyrin 284041-10-7 441070-87-7,
1,2,3-Triazolecarboxamide 441070-88-8 441070-92-4 441772-39-0,
Isobengazole 441772-43-6, Nagrestip 441772-66-3, Vinxaltine
441772-81-2, Sulfmosine 441774-07-8, Spicamycin D 441774-77-2,
Solverol 682329-63-1, Cytostatin 892553-42-3, Vitaxin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 60529-76-2, Thymopoietin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(receptor agonists, pharmaceutical formulation further including;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT 79217-60-0, Cyclosporin

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT 1397-89-3, Amphotericin B

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 and listeri?

10768 LISTERI?

L4 2 L1 AND LISTERI?

=> d l4 scan

L4 2 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K031-00

CC 1-6 (Pharmacology)

Section cross-reference(s): 10, 63

- TI Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms
- ST neoplastic lesion treatment incensole furanogermacrene compd; antitumor incensole furanogermacrene; antimicrobial incensole furanogermacrene
- IT Proteins
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A, immunomodulator based on, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Lymphoma
(B-cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Fusion proteins (chimeric proteins)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(BCR-ABL, antagonists, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Inflammation
(Crohn's disease, treatment of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Intestine, disease
(Crohn's, treatment of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Canarypox virus
(IL-2 of, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT GTPase-activating protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RasGAP, inhibitors, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Sdi 1, mimetics, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Skin, neoplasm
(Sezary syndrome; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Lymphoma
(T-cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Transcription factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(WT1 (Wilms' tumor suppressor 1), therapy based on; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Keratosis
(actinic; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Lung, neoplasm
(adenocarcinoma; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Melanoma
(amelanotic; incensole and furanogermacrene and compds. as antitumor

and antimicrobial agents)

IT Urokinase-type plasminogen activator receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-dorsalizing morphogenetic protein-1, pharmaceutical formulation
 further including; incensole and furanogermacrens and compds. as
 antitumor and antimicrobial agents)

IT Antitumor agents
 (antineoplastons, pharmaceutical formulation further including;
 incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT Nutrients
 (antinutrients, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Drug resistance
 (antitumor; incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT Lung, disease
 (aspergillosis, treatment of immunodysregulation condition caused by;
 incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT Infection
 (bacterial, intracellular or extracellular, treatment of
 immunodysregulation condition caused by; incensole and furanogermacrens
 and compds. as antitumor and antimicrobial agents)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (c-Raf, antagonists, pharmaceutical formulation further including;
 incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT Mycosis
 (candidiasis, treatment of immunodysregulation condition caused by;
 incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT Prostate gland, neoplasm
 (carcinoma, pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Ovary, neoplasm
 Stomach, neoplasm
 (carcinoma; incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT Mycobacterium
 (cell wall sk and monophosphoryl lipid A, pharmaceutical formulation
 further including; incensole and furanogermacrens and compds. as
 antitumor and antimicrobial agents)

IT Diterpenes
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cembranoid, alcs.; incensole and furanogermacrens and compds. as
 antitumor and antimicrobial agents)

IT Diterpenes
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cembranoid; incensole and furanogermacrens and compds. as antitumor

and antimicrobial agents)

IT Uterus, disease
(cervix, dysplasia; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Uterus, neoplasm
(cervix; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Porphyrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorins, benzo-, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Porphyrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorins, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-, enteric coating of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Intestine, neoplasm
(colon, carcinoma; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Intestine, neoplasm
(colon, polyp; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Intestine
(colon, precancerous lesion in; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Carcinoma
Intestine, neoplasm
(colon; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Polyoxalkylenes, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with pyridoxylated Hb; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Quinones
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclopentantraquinones, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Stem cell
(division inhibitors, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery systems containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug targeting to HIV infected cells using; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Tumor antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (drug targeting with monoclonal antibody to; incensole and
 furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Bronchi, disease
 Prostate gland, disease
 (dysplasia; incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

IT Skin, neoplasm
 (dysplastic nevus syndrome; incensole and furanogermacrene and compds.
 as antitumor and antimicrobial agents)

IT Dendritic cell
 (enhancement of endogenous precursor; incensole and furanogermacrene
 and compds. as antitumor and antimicrobial agents)

IT Heat-shock proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (enhancement of endogenous; incensole and furanogermacrene and compds.
 as antitumor and antimicrobial agents)

IT Polymers, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enteric coating of; incensole and furanogermacrene and compds. as
 antitumor and antimicrobial agents)

IT Drug delivery systems
 (enteric-coated; incensole and furanogermacrene and compds. as
 antitumor and antimicrobial agents)

IT Drug delivery systems
 (enteric; incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

IT Escherichia coli
 (enterohemorrhagic, treatment of immunodysregulation condition caused
 by infection with; incensole and furanogermacrene and compds.
 as antitumor and antimicrobial agents)

IT Escherichia coli
 (enteroinvasive, treatment of immunodysregulation condition caused by
infection with; incensole and furanogermacrene and compds. as
 antitumor and antimicrobial agents)

IT Escherichia coli
 (enteropathogenic, treatment of immunodysregulation condition caused by
infection with; incensole and furanogermacrene and compds. as
 antitumor and antimicrobial agents)

IT Escherichia coli
 (enterotoxigenic, treatment of immunodysregulation condition caused by
infection with; incensole and furanogermacrene and compds. as
 antitumor and antimicrobial agents)

IT Lung, neoplasm
 (epidermoid; incensole and furanogermacrene and compds. as antitumor
 and antimicrobial agents)

IT Gene therapy
 (erythrocyte, vector system, pharmaceutical formulation further
 including; incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (for apoptosis, modulators of, pharmaceutical formulation further
 including; incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

IT Carcinoma
 (gastric; incensole and furanogermacrene and compds. as antitumor and

antimicrobial agents)

IT Multidrug resistance
(gene inhibitor, pharmaceutical formulation further including;
incensole and furanogermacreins and compds. as antitumor and
antimicrobial agents)

IT Apoptosis
(gene modulators or regulators, pharmaceutical formulation further
including; incensole and furanogermacreins and compds. as antitumor and
antimicrobial agents)

IT Erythrocyte
(gene therapy vector system, pharmaceutical formulation further
including; incensole and furanogermacreins and compds. as antitumor and
antimicrobial agents)

IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp120env, drug targeting to HIV infected cells using
antibodies to; incensole and furanogermacreins and compds. as antitumor
and antimicrobial agents)

IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp160env, drug targeting to HIV infected cells using
antibodies to; incensole and furanogermacreins and compds. as antitumor
and antimicrobial agents)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(immunostimulant, pharmaceutical formulation further including;
incensole and furanogermacreins and compds. as antitumor and
antimicrobial agents)

IT Chemotherapy
Parasiticides
Radiotherapy
Surgery
(in combination with; incensole and furanogermacreins and compds. as
antitumor and antimicrobial agents)

IT Adrenal gland, neoplasm
Anti-AIDS agents
Anti-infective agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antidiarrheals
Antitumor agents
B-cell leukemia
Bladder, neoplasm
Brain, neoplasm
Burn
Central nervous system, neoplasm
Drug delivery systems
Enterococcus faecalis
Hairy cell leukemia
Hematopoietic neoplasm
Hodgkin's disease
Human
Leukemia
Leukemia
Lymphoma
Mammary gland, neoplasm

Melanoma
 Monocytic leukemia
 Mouth, neoplasm
 Multiple myeloma
 Myeloid leukemia
 Myelomonocytic leukemia
 Neoplasm
 Newborn
 Ovary, neoplasm
 Pancreas, neoplasm
 Prostate gland, neoplasm
 Sarcoma
 Staphylococcus aureus
 Stomach, neoplasm
 T-cell leukemia
 Testis, neoplasm
 (incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Polyoxyalkylenes, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Yeast
 (infection with, treatment of immunodysregulation condition caused by; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Intestine, disease
 (inflammatory, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Cartilage
 (inhibitor derived from, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Stem cell
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Insulin-like growth factor I receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Translation, genetic
 (inhibitors of, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Signal transduction, biological
 (inhibitors or modulators, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Macrophage migration inhibitory factor
 Ras proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Insulin-like growth factor-binding proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (insulin-like growth factor I-binding, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as

antitumor and antimicrobial agents)

IT Parasite
(intracellular or extracellular infection with, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Intestine, disease
(irritable bowel syndrome, treatment of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Digestive tract
(irritation, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Paracoccidioides
(juvenile paracoccidioidomycosis, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lung, neoplasm
(large-cell carcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Bladder, disease
Skin, disease
(lesions; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Virus
(lipid envelope, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipophilic disaccharide, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(liposomes; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lytic, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Pulverization
(micronization; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Double stranded RNA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mismatched, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, conjugates, with liposome or carbohydrate vehicles, to tumor-associated antigen; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal, to human chorionic gonadotropin, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lipid A
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monophosphates, and mycobacterium cell wall sk, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Nerve, disease
 (motor, treatment of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Gram-positive bacteria
 (multi-drug resistant; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Gene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (multidrug resistance, inhibitor, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (nasal; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Nerve, neoplasm
 (neuroblastoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antioxidants
 (nitroxide, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lymphocyte
 (null cell, leukemia; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interleukin 2
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of canarypox virus, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Cytokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (oral inducer, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (oral; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (ovarian; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (parenterals; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antiviral agents
 (pharmaceutical formulation further containing; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulation further containing; incensole and

furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Angiogenesis inhibitors
 Antiandrogens
 Antiestrogens
 Antivenoms
 Cytotoxic agents
 Immunostimulants
 Mycobacterium bovis
 Venoms
 (pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Antisense oligonucleotides
 Estrogens
 Hormones, animal, biological studies
 Interleukins
 Leukemia inhibitory factor
 Neuregulin 1
 Oligonucleotides
 Polyamines
 Ribozymes
 Steroids, biological studies
 Taxanes
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Disease, animal
 (polyposis syndrome; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Fatty acids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (poppy seed-oil, Et esters, labeled with iodine-131, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Central nervous system, disease
 Kidney, disease
 Lung, disease
 Mammary gland, disease
 Stomach, disease
 (precancerous lesion in; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (prodrugs; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (prostatic, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (pulmonary adenocarcinoma; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (pulmonary large-cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (pulmonary small-cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Hemoglobins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (reaction products, with pyridoxal phosphate, conjugates with polyoxyethylene, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (rectal; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Kidney, neoplasm
 (renal cell carcinoma; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (renal cell; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Antitumor agents
 (resistance to; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Ribosome-inactivating proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (saporin, fibroblast growth factor conjugates; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (senescence-derived inhibitor 1, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Oligonucleotides
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sense, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Shock (circulatory collapse)
 (septic, treatment of; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (single chain antigen binding protein, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Cell wall
 (sk of mycobacteria and monophosphoryl lipid A, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Leukemia
 (small cell; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Lung, neoplasm
 (small-cell carcinoma; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Neoplasm
 (solid; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Carcinoma
 (squamous cell; incensole and furanogermacreins and compds. as antitumor

and antimicrobial agents)

IT Drug delivery systems
(sublingual; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Glycosaminoglycans, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Lupus erythematosus
(systemic, treatment of; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Human immunodeficiency virus
(targeting to cells infected with; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thymopoietin, agonists, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(topical; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Stem cell factor
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(totipotent, pharmaceutical formulation further including; incensole and furanogermacreins and compds. as antitumor and antimicrobial agents)

IT Adeno-associated virus
Balantidium
Balantidium coli
Borrelia
Campylobacter
Candida
Coronavirus
Cryptococcus (fungus)
Cryptosporidium
DNA viruses
Entamoeba
Entamoeba histolytica
Filovirus
Flavivirus
Haemophilus
Hantavirus
Human papillomavirus
Human parainfluenza virus
Human poliovirus
Influenza virus
Legionella
Leishmania
Leishmania braziliensis
Leishmania donovani
Leishmania mexicana
Leishmania tropica
Listeria
Measles virus
Mycoplasma
Papillomavirus

Pestivirus
 Picornaviridae
 Plasmodium berghei
 Plasmodium falciparum
 Plasmodium malariae
 Plasmodium ovale
 Plasmodium vivax
 Pneumocystis
 Pneumocystis carinii
 Poxviridae
 Pseudomonas
 RNA viruses
 Respiratory syncytial virus
 Retroviridae
 Rhinovirus
 Rubivirus
 Salmonella
 Shigella
 Staphylococcus
 Streptococcus
 Togaviridae
 Toxoplasma
 Toxoplasma gondii
 Trichomonas
 Trichomonas vaginalis
 Trypanosoma
 Trypanosoma brucei
 Trypanosoma cruzi
 Trypanosoma gambiense
 Trypanosoma rhodesiense
 Vibrio
 Yersinia

(treatment of immunodysregulation condition caused by infection
 with; incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

- IT Gamma ray

(treatment of immunodysregulation condition caused by treatment with;
 incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)
- IT Corticosteroids, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (treatment of immunodysregulation condition caused by treatment with;
 incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)
- IT Nucleoside analogs

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (treatment of immunodysregulation condition caused by treatment with;
 incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)
- IT Immunosuppressants

Mycosis
 Protozoa
 Wound
 (treatment of immunodysregulation condition caused by; incensole and
 furanogermacrene and compds. as antitumor and antimicrobial agents)
- IT Arthritis
- Asthma

Autoimmune disease
 Cachexia
 Cirrhosis
 Diabetes mellitus
 Diarrhea
 Immune disease
 Multiple sclerosis
 Respiratory distress syndrome
 (treatment of; incensole and furanogermacrens and compds. as antitumor
 and antimicrobial agents)

IT Cytotoxic agents
 (tyrphostins, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (vaginal; incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT Infection
 (viral, treatment of immunodysregulation condition caused by; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Disease, animal
 (wasting, treatment of; incensole and furanogermacrens and compds. as
 antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (α , n1, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (α , n3, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (α , pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (α -2a, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (α -2b, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Lactams
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (β -, pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (β 1, a, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Interferons

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (γ, 1b, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 37221-79-7, Vasoactive intestinal peptide
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antagonist, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 9002-06-6, Thymidine kinase
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antagonists, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 505-60-2, Mustard
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anticancer, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 7585-39-9, β- Cyclodextrin 7585-39-9D, β- Cyclodextrin, hydroxypropyl derivs. 10016-20-3, α- Cyclodextrin 12619-70-4, Cyclodextrin 17465-86-0, γ- Cyclodextrin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as pharmaceutical carrier; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 80-62-6, Methyl methacrylate 2867-47-2, (2-Dimethylaminoethyl) methacrylate 9004-38-0, Cellulose acetate phthalate 34346-01-5, Poly(lactic acid-glycolic acid) 441015-98-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enteric coating of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 121749-39-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT 54-47-7D, Pyridoxal phosphate, reaction products with Hb conjugates 76-49-3, Bornyl acetate 80-57-9, Verbenone 87-44-5, β-Caryophyllene 88-84-6, β-Guaiene 99-49-0, Carvone 99-83-2, α-Phellandrene 99-87-6, p-Cymene 112-14-1, Octyl acetate 123-35-3, Myrcene 473-11-0, Eudesmane 489-80-5, Guaiane 495-61-4, β-Bisabolene 502-61-4, Farnesene 507-70-0, Borneol 511-59-1, β-Santalene 512-61-8, α-Santalene 515-12-8, Elemene 523-47-7, β-Cadinene 555-10-2, β-Phellandrene 562-74-3, Terpinen-4-ol 1335-14-4 1674-08-4, trans-Pinocarveol 1820-09-3, trans-Verbenol 2867-05-2, α-Thujene 3856-25-5, α-Copaene 4602-84-0, Farnesol 5208-59-3, β-Bourbonene 6753-98-6, Humulene 6895-56-3, β-Bergamotene 7663-66-3, Bergamotane 8007-35-0, Terpinyl acetate 8013-00-1, Terpinene 10178-38-8, Echinodol 14998-63-1D, Rhenium-186, etidronate complexes, biological studies 17627-44-0, α-Bisabolene 18794-84-8, β-Farnesene 19912-61-9, Furanodiene 20479-06-5, β-Ylangene 21698-66-8, Incensole oxide 21698-67-9, Incensole oxide acetate 22419-74-5, Incensole 25269-16-3, Isocembrene 25322-68-3D, conjugates with pyridoxylated Hb 28028-64-0, Germacrene 29063-28-3, Octanol 29350-73-0, Cadinene 31570-39-5, Cembrene-A 34701-53-6 35731-88-5, Isoincensole oxide 67921-02-2, Cembrenol 94325-73-2 94325-73-2D,

compds. 122537-31-9, Oplopane 441771-56-8, Isoincensole 441771-57-9, Isoincensole acetate 441771-74-0, SKB 4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 141436-78-4, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 52660-18-1, Casein kinase 1 366806-33-9, Casein kinase 2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors (ICOS), pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 144114-21-6, HIV-1 Protease
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further containing; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 70-18-8, Glutathione, biological studies 9030-21-1, Purine nucleoside phosphorylase 9040-48-6, Gelatinase 79747-53-8, Protein tyrosine phosphatase 79955-99-0, Stromelysin 80449-02-1, Tyrosine kinase 106096-93-9, Basic fibroblast growth factor 120178-12-3, Telomerase 131384-38-8, Ras farnesyltransferase 140879-24-9, Proteasome 141256-52-2, Matrilysin 141907-41-7, Matrix metalloproteinase 375798-61-1, Phosphatase, phosphoprotein
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 10102-43-9, Nitric oxide, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (modulators, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 9002-61-3, Chorionic gonadotropin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (monoclonal antibody to human, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 9068-38-6, Reverse transcriptase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nonnucleoside inhibitors of, pharmaceutical formulation further containing; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 1406-18-4, Vitamin E
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oil, as pharmaceutical carrier; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT 54-05-7, Chloroquine 54-42-2, Idoxuridine 60-54-8, Tetracycline 69-74-9, Cytarabine Hydrochloride 70-00-8, Trifluridine 80-08-0, Dapsone 90-34-6, Primaquine 100-33-4, Pentamidine 130-95-0, Quinine 443-48-1, Metronidazole 494-79-1, Melarsoprol 665-66-7, Amantadine Hydrochloride 1501-84-4, Rimantadine Hydrochloride 1910-68-5, Methisazone 3056-17-5, d4T 3736-81-0, Diloxanide furoate 5536-17-4, Vidarabine 7481-89-2, DdC 8064-90-2 9004-70-0, HE-2000 10500-82-0, Famotidine Hydrochloride 10540-97-3, Memotidine Hydrochloride 11006-77-2, Statolon 15176-29-1, Edoxudine 15185-43-0, DOTC 19387-91-8, Tinidazole 19885-51-9, Aranotin 22994-85-0, Benznidazole 23256-30-6, Nifurtimox 25526-93-6, Alovudine 27591-69-1, Tilorone Hydrochloride

27762-78-3, Kethoxal 29984-33-6, Vidarabine Phosphate 30516-87-1, AZT 35607-20-6, Avridine 36791-04-5, Ribavirin 36983-81-0, Fosfonet Sodium 37338-39-9 39809-25-1, Penciclovir 51867-87-9 53230-10-7, Mefloquine 56219-57-9, Arildone 59277-89-3, Acyclovir 63198-97-0, Viroxime 63585-09-1, Foscarnet Sodium 63968-64-9D, Artemisinin, derivs. 68693-30-1, Somantadine Hydrochloride 69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69655-05-6, DdI 69657-51-8, Acyclovir Sodium 69756-53-2, Halofantrine 72301-78-1, Zinviroxime 72301-79-2, Enviroxime 73514-87-1, Fosarilate 77181-69-2, Sorivudine 80883-55-2, Enviradene 82410-32-0, Ganciclovir 84408-37-7, Desciclovir 85087-20-3, Doxycycline 87495-31-6, Disoxaril 95233-18-4, Atovaquone 100817-46-7, Stibogluconic acid 104227-87-4, Famciclovir 106362-32-7, Peptide T 106941-25-7, PMEa 107910-75-8, Ganciclovir Sodium 110042-95-0, Acemannan 110143-10-7, Lodenosine 113852-37-2, Cidofovir 124436-59-5, Pirodavis 124832-27-5, Valacyclovir Hydrochloride 127759-89-1, Lobucavir 127779-20-8, Saquinavir 129618-40-2, Nevirapine 132210-43-6, Cipamfylline 134678-17-4, 3TC 136470-78-5, Abacavir 136817-59-9, Delavirdine 137487-62-8, Alvircept Sudotox 138540-32-6, Atevirdine Mesylate 141204-94-6, Co-artemether 142340-99-6 142632-32-4, Calanolide A 143491-57-0, Coviracil 145514-04-1, DAPD 147127-20-6, Tenofovir 147221-93-0, Delavirdine Mesylate 147318-81-8, KNI-272 147362-57-0, Loviride 149845-06-7, Saquinavir Mesylate 149950-60-7, Emivirine 150378-17-9, Indinavir 153127-49-2, ALX40-4C 154598-52-4, DMP 266 155148-31-5, AMD 3100 155213-67-5, Ritonavir 156879-70-8 159519-65-0, Pentafuside 159989-64-7, Nelfinavir 163451-80-7 170020-61-8, FP-21399 174484-41-4, Tipranavir 177932-89-7, DMP-450 178979-85-6, AG 1549 185220-03-5, PNU142721 192725-17-0, ABT-378 214287-88-4, DPC961 216863-66-0, L-756423 251562-00-2, T-1249 383198-56-9, BW 141 383198-57-0, BMS-232630 383198-58-1, PRO 542

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 50-07-7, Mutamycin 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-19-0, Mitotane 53-43-0, DHEA 53-79-2, Puromycin 54-71-7, Pilocarpine hydrochloride 54-91-1, Pipobroman 55-21-0D, Benzamide, N-substituted compds. 55-86-7, Mechlorethamine Hydrochloride 55-86-7D, Nitrogen mustard, derivs. 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl oestradiol 57-83-0, Progesterone, biological studies 58-05-9, Leucovorin 58-58-2, Puromycin Hydrochloride 59-05-2, Methotrexate 66-75-1, Uracil Mustard 83-89-6, Acriquine 101-60-0, Porphyrin 106-60-5, Aminolevulinic acid 114-70-5, Sodium phenylacetate 122-79-2, Phenylacetate 125-45-1, Azetepa 125-84-8, Aminogluthetamide 127-07-1, Hydroxyurea 143-67-9, Vinblastine Sulfate 145-63-1, Suramin 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 302-49-8, Uredepia 302-79-4, Tretinoin 305-03-3, Chlorambucil 320-67-2, Azacitidine 359-83-1, Pentazocine 364-62-5, Metoclopramide 366-70-1, Procarbazine Hydrochloride 378-44-9, Betamethasone 423-55-2, Perflubron 459-86-9, Mitoguanzone 465-65-6, Naloxone 472-15-1, Betulinic acid 481-29-8, Epiandrosterone 518-28-5, Podophyllotoxin 520-85-4, Medroxyprogesterone 521-12-0, Dromostanolone Propionate 536-59-4, Perillyl alcohol 548-04-9, Hypericin 566-48-3, Formestane 569-57-3, Chlorotrianisene 578-95-0D, Acridone, imidazo derivs. 578-95-0D, Acridone, propylbis derivs. 595-33-5, Megestrol Acetate

645-05-6, Altretamine 646-08-2, β -Alethine 671-16-9, Procarbazine
 801-52-5, Porfiromycin 865-21-4, Vinblastine 911-45-5, Clomifene
 968-93-4, Testolactone 1271-19-8, Titanocene dichloride 1402-81-9,
 Ambomycin 1403-99-2, Mitogillin 1404-00-8, Mitomycin 1404-15-5,
 Nogalamycin 1404-20-2, Peliomycin 1404-64-4, Sparsomycin 1661-29-6,
 Meturedopa 1972-08-3, Dronabinol 1980-45-6, Benzodepa 2068-78-2,
 Vincristine Sulfate 2353-33-5, Decitabine 2508-89-6 2608-24-4,
 Piposulfan 2809-21-4D, Etidronic acid, rhenium-186 complexes
 2919-66-6, Melengestrol acetate 2998-57-4, Estramustine 2998-57-4D,
 Estramustine, analogs 3073-59-4, Hexamethylene bisacetamide 3094-09-5,
 Doxifluridine 3562-63-8, Megestrol 3778-73-2, Ifosfamide 3930-19-6,
 Streptonigrin 4105-38-8 4291-63-8, Cladribine 4342-03-4, Dacarbazine
 4342-07-8 4803-27-4, Anthramycin 5072-26-4, Buthionine sulfoximine
 5373-42-2, Thaliblastine 5508-58-7, Andrographolide 5579-27-1,
 Simtrazene 5581-52-2, Thiamiprine 5696-17-3, Epipropidine 6157-87-5,
 Trestolone Acetate 7281-31-4, Vinglycinatate Sulfate 7440-06-4D,
 Platinum, lipophilic compds. or complexes 7440-06-4D, Platinum, triamine
 complexes 7644-67-9, Azotomycin 7689-03-4D, Camptothecin, derivs.
 7724-76-7, Riboprime 7761-45-7, Metoprime 8052-16-2, Cactinomycin
 9002-71-5, Thyroid-stimulating hormone 9014-02-2, Zinostatin
 9014-42-0, Thrombopoietin 9014-42-0D, Thrombopoietin, mimetics
 9015-68-3, Asparaginase 9027-98-9 9041-93-4, Bleomycin Sulfate
 9050-67-3, Sizofiran 10043-49-9, Gold-198, biological studies
 10087-89-5, Enpromate 10318-26-0, Mitolactol 10403-51-7, Mitindomide
 10540-29-1, Tamoxifen 11002-22-5, Apurinic acid 11029-06-4, Elemene
 11043-98-4, Mitocromin 11043-99-5, Mitomalcin 11056-06-7, Bleomycin
 11056-12-5, Cirolemycin 11056-14-7, Mitocarcin 11056-15-8, Mitosper
 12713-07-4D, Verdin, compds. 13010-47-4, Lomustine 13311-84-7,
 Flutamide 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol
 13909-09-6, Semustine 14769-73-4, Levamisole 15475-56-6, Methotrexate
 Sodium 15639-50-6, Safingol 15663-27-1, Cisplatin 17021-26-0,
 Calusterone 17902-23-7, Tegafur 18378-89-7, Plicamycin 18416-85-8,
 Lombricine 18556-44-0, Vinrosidine Sulfate 18588-57-3, Etoprine
 18883-66-4, Streptozocin 19916-73-5, O6-Benzylguanine 20098-14-0,
 Idramantone 20537-88-6, Amifostine 20638-84-0, Retinamide
 20830-81-3, Daunorubicin 21059-48-3, Veramine 21679-14-1, Fludarabine
 22668-01-5, Etanidazole 23214-92-8, Doxorubicin 23541-50-6,
 Daunorubicin Hydrochloride 23593-75-1, Clotrimazole 24280-93-1,
 Mycophenolic Acid 24584-09-6, Dexrazoxane 25316-40-9, Adriamycin
 27302-90-5, Oxisuran 27314-97-2, Tirapazamine 27548-93-2D, Baccatin
 III, derivs. 27686-84-6, Masoprocol 29069-24-7, Prednimustine
 29767-20-2, Teniposide 30303-65-2, Docosanol 30387-51-0, Asperlin
 30868-30-5, Pyrazofurin 31430-18-9, Nocodazole 31441-78-8,
 Mercaptopurine 32954-58-8, Ipomeanol 33069-62-4, Paclitaxel
 33069-62-4D, Paclitaxel, analogs and derivs. 33419-42-0, Etoposide
 35301-24-7, Cedefingol 35846-53-8, Maytansine 35943-35-2, Triciribine
 36508-71-1, Zorubicin Hydrochloride 37717-21-8, Flurocitabine
 38270-90-5, Strontium Chloride Sr 89 38321-02-7, Dexverapamil
 39325-01-4, Picibanil 40391-99-9, Pamidronic acid 41575-94-4,
 Carboplatin 41729-52-6, Dezaguanine 41992-22-7, Spirogermanium
 Hydrochloride 42228-92-2, Acivicin 42616-25-1, Methioninase
 50264-69-2, Lonidamine 51264-14-3, Amsacrine 51321-79-0, Sparfosic
 acid 52128-35-5, Trimetrexate 52205-73-9, Estramustine Phosphate
 Sodium 52794-97-5, Carubicin Hydrochloride 53643-48-4, Vindesine
 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54081-68-4,
 Vinleurosine Sulfate 54824-17-8, Mitonafide 55435-65-9, Acodazole
 Hydrochloride 56390-09-1, Epirubicin Hydrochloride 56420-45-2,
 Epirubicin 56605-16-4, Spiromustine 56741-95-8, Bropirimine

57381-26-7, Irsogladine 57576-44-0, Aclarubicin 57773-63-4,
Triptorelin 57773-65-6, Deslorelin 57852-57-0, Idamycin 57998-68-2,
Diaziquone 58066-85-6, Miltefosine 58525-82-9, Azatyrosine
58957-92-9, Idarubicin 58970-76-6, Ubenimex 59653-73-5, Teroxirone
59917-39-4, Vindesine Sulfate 59989-18-3, 5-Ethynyluracil 60084-10-8,
Tiazofurin 60203-57-8, Prostaglandin J2 60940-34-3, Ebselen
61825-94-3, Oxaliplatin 61966-08-3, Triciribine Phosphate 62304-98-7,
Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62816-98-2,
Ormaplatin 62928-11-4, Iproplatin 63590-19-2, Balanol 63612-50-0,
Nilutamide 63950-06-1, Esorubicin Hydrochloride

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfosfate 65222-35-7,
Pazelliptine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide
65807-02-5, Goserelin 65886-71-7, Fazarabine 66569-27-5, Sparfosate
Sodium 66849-34-1, Dexifosfamide 67699-41-6, Vinzolidine Sulfate
68278-23-9, Eflornithine Hydrochloride 68475-42-3, Anagrelide
69839-83-4, Didox 70052-12-9, Eflornithine 70384-29-1, Peplomycin
Sulfate 70476-82-3, Mitoxantrone Hydrochloride 70641-51-9, Edelfosine
70711-40-9, Ametantrone Acetate 71294-60-5, Rohitukine 71439-68-4,
Bisantrene Hydrochloride 71486-22-1, Vinorelbine 71522-58-2,
Forfenimex 71628-96-1, Menogaril 72238-02-9D, Retelliptine, demethyl
derivs. 72496-41-4, Pirarubicin 72629-69-7, Sarcophytol A
72732-56-0, Piritrexim 72741-87-8, Swainsonine 73105-03-0,
Pentamustine 74149-70-5, Parabactin 74381-53-6, Leuprolide Acetate
74790-08-2, Spiroplatin 75219-46-4, Atrimustine 75330-75-5, Lovastatin
75607-67-9, Fludarabine Phosphate 75775-33-6D, Purpurin, compds.
75957-60-7, Splenopentin 76932-56-4, Nafarelin 77016-85-4, Plomestane
77327-05-0, Didemnin B 77599-17-8, Panomifene 77858-21-0, Velaresol
78113-36-7, Romurtide 78186-34-2, Bisantrene 79778-41-9, Neridronic
acid 79831-76-8, Castanospermine 80451-05-4, Cecropin B 80576-83-6,
Edatrexate 80663-95-2 80841-47-0, Asulacrane 81424-67-1, Caracemide
81965-43-7, SarCNU 82230-03-3, Carbetimer 82413-20-5, Droloxifene
82707-54-8, Neutral endopeptidase 82855-09-2D, Combretastatin, analogs
82952-64-5, Trimetrexate Glucuronate 83086-73-1, Tubulozole
Hydrochloride 83150-76-9, Octreotide 83200-11-7, Vinepidine Sulfate
83519-04-4, Ilmofofosine 83997-75-5, Iododoxorubicin 84030-84-2,
Telluopyrylium 84088-42-6, Roquinimex 84371-65-3, Mifepristone
84412-94-2, Ruboxyl 85465-82-3, Thymotrinan 85622-93-1, Temozolomide
85754-59-2, Ambamustine 85969-07-9, Budotitane 85977-49-7,
Tauromustine 86976-56-9, Betaclamycins 87005-03-6, Panaxytriol
87434-82-0, Dezaguanine Mesylate 87806-31-3, Porfimer Sodium
87810-56-8, Fostriecin 87860-39-7, Fostriecin Sodium 88303-60-0,
Losoxantrone 88303-61-1, Losoxantrone Hydrochloride 89565-68-4,
Tropisetron 89778-26-7, Toremifene 89778-27-8, Toremifene Citrate
90357-06-5, Bicalutamide 90996-54-6, Rhizoxin 92047-76-2,
Tetrachlorodecaoxide 92118-27-9, Fotemustine 92788-10-8, Rogletimide
92803-82-2, Aphidicolin glycinate 94079-80-8, Cicaprost 95058-81-4,
Gemcitabine 95734-82-0, Nedaplatin 95933-72-5, Amidox 96201-88-6,
Brequinar Sodium 96301-34-7, Atamestane 96346-61-1, Onapristone
96389-68-3, Crisnatol 96389-69-4, Crisnatol Mesylate 96392-96-0,
Dexormaplatin 96892-57-8, Hepsulfam 97068-30-9, Elsamitrucin
97534-21-9, Merbarone 97682-44-5, Irinotecan 97752-20-0, Droloxifene
Citrate 97919-22-7 98319-26-7, Finasteride 98383-18-7, Ecomustine
98631-95-9, Sobuzoxane 99009-20-8, Pyrazoloacridine 99011-02-6,
Imiquimod 99283-10-0, Molgramostim 99614-02-5, Ondansetron

100286-90-6, Irinotecan Hydrochloride 100324-81-0, Lisofylline
 102396-24-7, Jasplakinolide 102676-31-3, Fadrozole Hydrochloride
 102676-47-1, Fadrozole 102822-56-0, Mannostatin A 103222-11-3,
 Vapreotide 103612-80-2 104493-13-2, Adecyphenol 105118-12-5,
 Piroxantrone Hydrochloride 105149-04-0, Osaterone 105615-58-5,
 Oxaunomycin 105844-41-5, Plasminogen activator inhibitor 106096-93-9D,
 Basic fibroblast growth factor, saporin conjugates 106400-81-1,
 Lometrexol 107000-34-0, Zanolterone 107256-99-5, Tamoxifen methiodide
 107868-30-4, Exemestane 108736-35-2, Lanreotide 108852-90-0,
 Nemorubicin 109837-67-4, Cycloplatan 110267-81-7, Amrubicin
 110311-27-8, Sulofenur 110314-48-2, Adozelesin 110690-43-2, Emitefur
 110942-02-4, Aldesleukin 110942-08-0, Luprolide 111490-36-9,
 Zeniplatin 111523-41-2, Enloplatin 112515-43-2, Topsentin
 112522-64-2, Acetyldinaline 112809-51-5, Letrozole 112859-71-9,
 Fluasterone 112887-68-0, Raltitrexed 112965-21-6, Calcipotriol
 114084-78-5, Ibandronic acid 114285-68-6, Lentinan sulfate
 114517-02-1, Fosquidone 114977-28-5, Taxotere 115150-59-9, Antagonist
 G 115308-98-0, Tallimustine 115566-02-4, Bistratene A 115575-11-6,
 Liarozole 115956-12-2, Dolasetron 116057-75-1, Idoxifene
 117048-59-6, Combretastatin A4 117091-64-2, Etoposide Phosphate
 118292-40-3, Tazarotene 119169-78-7, Epristeride 119413-54-6,
 Topotecan Hydrochloride 119813-10-4, Carzelesin 120287-85-6,
 Cetorelix 120408-07-3, Lometrexol Sodium 120500-15-4, Leinamycin
 120511-73-1, Anastrozole 120685-11-2, Benzoylstauosporine
 121181-53-1, Filgrastim 121263-19-2, Calphostin C 121288-39-9,
 Loxoribine 121547-04-4, Mirimostim 122111-03-9, Gemcitabine
 Hydrochloride 122341-38-2, Temoporfin 122431-96-3 122898-63-9,
 Phenazinomycin 123040-69-7, Azasetron 123258-84-4, Itasetron
 123760-07-6, Zinostatin stimalamer 123774-72-1, Sargramostim
 123830-79-5, Teloxantrone Hydrochloride 123948-87-8, Topotecan
 124012-42-6, Galocitabine 124689-65-2D, Cryptophycin A, derivs.
 124784-31-2, Erbulozole 124904-93-4, Ganirelix 125317-39-7,
 Vinorelbine Tartrate 125392-76-9, Acylfulvene 125533-88-2, Mofarotene
 126297-39-0, Lissoclinamide 7 126443-96-7, Napavin 127984-74-1,
 Lanreotide Acetate 128505-88-4, Naphterpin 128768-09-2, Placetin A
 128768-11-6, Placetin B 129497-78-5, Verteporfin 129564-92-7, Azatoxin
 129655-21-6, Bizelesin 129731-10-8, Vorozole 130167-69-0, Pegaspargase
 130288-24-3, Duocarmycin SA 130364-39-5, Rubiginone B1 130370-60-4,
 Batimastat 131190-63-1, Saintopin 132036-88-5, Ramosetron
 132073-72-4, Tetrazomine 133432-71-0, Peldesine 134088-74-7,
 Nartograstim 134381-30-9, Conagenin 134523-84-5 134633-29-7,
 Tecogalan Sodium 134861-62-4, Dioxamycin 135257-45-3, Crambescidin 816
 135381-77-0, Flezelastine 135383-02-7, Stipiamide 135558-11-1,
 Lobaplatin 135819-69-1 135968-09-1, Lenograstim 137018-54-3,
 Okicenone 137099-09-3, Turosteride 137219-37-5, Dehydrodidemnin B
 137647-92-8, Axinastatin 1 137964-32-0 139755-79-6, Safingol
 Hydrochloride 140207-93-8, Pentosan polysulfate sodium 140703-49-7,
 Meterelin 142880-36-2, Ilomastat 144885-51-8, Sodium borocaptate
 144916-42-7, Sonermin 145124-30-7, Bisnafide dimesylate 145858-50-0,
 Liarozole Hydrochloride 146426-40-6, Flavopiridol 148317-76-4, Oracin
 148584-53-6 148717-58-2, Palauamine 148717-90-2, Squalamine
 149204-42-2, Kahalalide F

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 149260-80-0, Mycaperoxide B 149355-77-1, Lamellarin-N triacetate
 149633-91-0, Leptolstatin 149715-96-8, Spongistatin 1 149882-10-0,

Lurtotecan 150829-93-9, Nisamycin 151272-78-5, Antarelix
 152923-56-3, Dacliximab 153723-34-3, Axinastatin 2 153723-35-4,
 Axinastatin 3 154039-60-8, Marimastat 154229-19-3, Abiraterone
 154248-96-1, Iroplact 154277-21-1, Cypemycin 154361-50-9, Capecitabine
 155233-30-0, Curacin A 156586-89-9, Edrecolomab 156790-85-1, Variolin
 B 157078-48-3, Isohomohalichondrin B 157857-21-1, Maspin
 158792-24-6, Collismycin A 158792-25-7, Collismycin B 168482-36-8,
 Cryptophycin 8 172793-30-5 173046-02-1, Thiocoraline 174305-65-8,
 Breflate 181887-82-1, Nitrullin 188364-40-1, CARN 700 200139-38-4,
 Suradista 212894-59-2, Pentozole 246252-04-0, Lutetium texaphyrin
 246252-06-2, Gadolinium texaphyrin 284041-10-7 441070-87-7,
 1,2,3-Triazolecarboxamide 441070-88-8 441070-92-4 441772-39-0,
 Isobengazole 441772-43-6, Nagrestip 441772-66-3, Vinxaltine
 441772-81-2, Sulfmosine 441774-07-8, Spicamycin D 441774-77-2,
 Solverol 682329-63-1, Cytostatin 892553-42-3, Vitaxin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 60529-76-2, Thymopoietin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (receptor agonists, pharmaceutical formulation further including;
 incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT 79217-60-0, Cyclosporin

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (treatment of immunodysregulation condition caused by treatment with;
 incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT 1397-89-3, Amphotericin B

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (treatment of immunodysregulation condition caused by treatment with;
 incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 2 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM A61K039-00

ICS A61K039-39; A61K038-19; A61K039-21; A61K039-145; A61K039-02;
 A61K039-002; A61K009-00; C07K014-16; A61K039-39; A61K038-19

CC 15-2 (Immunochemistry)

Section cross-reference(s): 63

TI Mucosal cytotoxic T lymphocyte responses

ST mucosal cytotoxic T lymphocyte antigen vaccine

IT Proteins, specific or class

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (A; soluble antigen for induction of mucosal cytotoxic T lymphocyte
 responses)

IT Glycerides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (C8-10; soluble antigen for induction of mucosal cytotoxic T lymphocyte
 responses)

IT Gene, microbial

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (HIV-1 gp160; soluble antigen for induction of mucosal cytotoxic T

lymphocyte responses)

IT Reagents
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (absorption-promoting; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Immunostimulants
 (adjuvants; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT T cell (lymphocyte)
 (binding agent; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Drug delivery systems
 (carriers; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Toxins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cholera; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Vaccines
 (cluster peptide vaccine construct; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Intestine
 (colon, delivery; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Intestine
 (colon, distal, delivery; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT T cell (lymphocyte)
 (cytotoxic; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Drug delivery systems
 (enemas, rectal; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Toxins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enterotoxins, heat-labile; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Drug delivery systems
 (gels, rectal; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Drug delivery systems
 (gels, topical, rectal; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Envelope proteins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (gp160env, HIV-1; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Escherichia coli
 (heat labile enterotoxin; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Diglycerides
 Glycerides, biological studies
 Monoglycerides
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hydrogenated coco monoglycerides, diglycerides and triglycerides; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Intestine
 (large, sigmoid colon delivery; soluble antigen for induction of mucosal

cytotoxic T lymphocyte responses)

IT Fatty acids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medium-chain; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Ligands
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mucosal tissue or T cell-specific protein; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Proteins, specific or class
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mucosal tissue or T cell-specific; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Immunity
 (mucosal, inducing antigen; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Toxins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pertussis; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Conformation
 (protein, V3 loop; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Drug delivery systems
 (rectal, intra-; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Emulsions
 Foams
 (rectal; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Intestine
 (rectum, delivery; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Animal virus
Bacteria (Eubacteria)
 CD8-positive T cell
 Cat (Felis catus)
 Giardia lamblia
 Hepatitis A virus
 Human immunodeficiency virus
 Human immunodeficiency virus 1
Infection
 Influenza virus
Listeria monocytogenes
 Mammal (Mammalia)
 Melanoma
 Micelles
 Mouse
 Pathogen
 Primate
 Protein sequences
 Protozoa
 Rotavirus
 Surfactants
 (soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT CD4 (antigen)
 CD8 (antigen)

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Antibodies
Cytokines
Enamines
Interleukin 12
Interleukin 2
Interleukin 7
Polyoxyalkylenes, biological studies
Prostate-specific antigen
Tumor necrosis factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Drug delivery systems
(suppositories, rectal; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Infection
(viral; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ ; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT 7384-98-7, Propyleneglycol dicaprylate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Sefsol 228; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT 10102-43-9, Nitric oxide, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(donor; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT 9002-10-2, Tyrosinase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanoma-derived; soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT 150374-59-7 150428-07-2 150428-10-7 150428-13-0 150428-17-4
162429-66-5 162429-70-1 162429-74-5 162429-75-6 162429-77-8
162429-78-9 162429-79-0 221224-34-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

IT 54-21-7, Sodium salicylate 541-50-4D, Acetoacetic acid, glycerol ester
7585-39-9D, β - Cyclodextrin, derivs. 9004-64-2
12619-70-4, Cyclodextrin 25322-68-3 57916-92-4,
Carbopol-934P 83869-56-1, GM-CSF
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(soluble antigen for induction of mucosal cytotoxic T lymphocyte responses)

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 15:12:19 ON 16 JUN 2008)

FILE 'CAPLUS' ENTERED AT 15:12:35 ON 16 JUN 2008

L1 44 S CYCLODEXTRIN AND BACTERIA? AND (INFECT? OR INVASI? OR DISEASE
L2 8 S L1 AND HYDROXYPROPYL
L3 1 S L2 AND LISTERI?
L4 2 S L1 AND LISTERI?

=> d l2 ibib 1-8

L2 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:162039 CAPLUS <<LOGINID::20080616>>
DOCUMENT NUMBER: 142:246191
TITLE: Formulations for counteracting infection of
mucosa or skin
INVENTOR(S): Thormar, Halldor; Kristmundsdottir, Thordis
PATENT ASSIGNEE(S): Iceland
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S.
Ser. No. 297,921.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20050043402	A1	20050224	US 2003-408235	20030408
WO 9820872	A1	19980522	WO 1997-DK524	19971114 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6596763	B1	20030722	US 1999-297921	19991216
PRIORITY APPLN. INFO.:			IS 1996-4386	A 19961114
			WO 1997-DK524	W 19971114
			US 1999-297921	A2 19991216
OTHER SOURCE(S):		MARPAT 142:246191		

L2 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964922 CAPLUS <<LOGINID::20080616>>
DOCUMENT NUMBER: 138:44707
TITLE: Therapeutic patch useful for the treatment of
hemorrhoids
INVENTOR(S): Buseman, Teri; Rolf, David
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020192273	A1	20021219	US 2002-120205	20020410 <--
PRIORITY APPLN. INFO.:			US 2001-298718P	P 20010615

L2 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:946849 CAPLUS <<LOGINID::20080616>>
DOCUMENT NUMBER: 138:29123
TITLE: Ophthalmic compositions containing quinolonecarboxylic acid
INVENTOR(S): Roy, Samir; Chandrasekaran, Santosh Kumar; Imamori, Katsumi; Asaoka, Takemitsu; Shibata, Akihiro; Takahashi, Masami; Bowman, Lyle M.
PATENT ASSIGNEE(S): Insite Vision Inc., USA; SSP Co., Ltd.
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020187193	A1	20021212	US 2001-840871	20010425 <--
US 6685958	B2	20040203		
US 20020182255	A1	20021205	US 2002-126513	20020422 <--
US 6699492	B2	20040302		
CA 2445408	A1	20021219	CA 2002-2445408	20020424 <--
WO 2002100309	A1	20021219	WO 2002-US12790	20020424 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002322002	A1	20021223	AU 2002-322002	20020424 <--
AU 2002322002	B2	20070125		
EP 1395215	A1	20040310	EP 2002-756088	20020424
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004529199	T	20040924	JP 2003-503136	20020424
US 20040157825	A1	20040812	US 2004-769019	20040202
PRIORITY APPLN. INFO.:			US 2001-840871	A2 20010425
			US 2002-126513	A 20020422
			WO 2002-US12790	W 20020424

OTHER SOURCE(S): MARPAT 138:29123

L2 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:928035 CAPLUS <<LOGINID::20080616>>
 DOCUMENT NUMBER: 138:16591
 TITLE: Quinolone carboxylic acid compositions for ocular and periocular infections
 INVENTOR(S): Roy, Samir; Chandrasekaran, Santosh Kumar; Imamori, Katsumi; Asaoka, Takemitsu; Shibata, Akihiro; Takahashi, Masami; Bowman, Lyle M.
 PATENT ASSIGNEE(S): Insight Vision Inc., USA; SSP Co., Ltd.
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U. S. Ser. No. 840,871.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020182255	A1	20021205	US 2002-126513	20020422 <--
US 6699492	B2	20040302		
US 20020187193	A1	20021212	US 2001-840871	20010425 <--
US 6685958	B2	20040203		
CA 2445408	A1	20021219	CA 2002-2445408	20020424 <--
WO 2002100309	A1	20021219	WO 2002-US12790	20020424 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002322002	A1	20021223	AU 2002-322002	20020424 <--
AU 2002322002	B2	20070125		
EP 1395215	A1	20040310	EP 2002-756088	20020424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529199	T	20040924	JP 2003-503136	20020424
US 20040157825	A1	20040812	US 2004-769019	20040202
PRIORITY APPLN. INFO.:			US 2001-840871	A2 20010425
			US 2002-126513	A 20020422
			WO 2002-US12790	W 20020424

OTHER SOURCE(S): MARPAT 138:16591

L2 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:521462 CAPLUS <<LOGINID::20080616>>
 DOCUMENT NUMBER: 137:88442
 TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms
 INVENTOR(S): Shanahan-Pendergast, Elisabeth
 PATENT ASSIGNEE(S): Ire.
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102 <--
WO 2002053138	A3	20020919		
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
AU 2002219472	A1	20020716	AU 2002-219472	20020102 <--
EP 1351678	A2	20031015	EP 2002-727007	20020102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040092583	A1	20040513	US 2004-250535	20040102
PRIORITY APPLN. INFO.:			IE 2001-2	A 20010102
			WO 2002-IE1	W 20020102
OTHER SOURCE(S):		MARPAT 137:88442		

L2 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:816495 CAPLUS <<LOGINID::20080616>>
 DOCUMENT NUMBER: 135:362574
 TITLE: Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
 INVENTOR(S): Judice, J. Kevin; Shaw, Jeng-Pyng; Mu, Yongqi; Conner, Michael W.
 PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082971	A2	20011108	WO 2001-US14000	20010501 <--
WO 2001082971	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408008	A1	20011108	CA 2001-2408008	20010501 <--
US 20020077280	A1	20020620	US 2001-846893	20010501 <--
US 6858584	B2	20050222		
EP 1278549	A2	20030129	EP 2001-932810	20010501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010530	A	20030408	BR 2001-10530	20010501
JP 2003531869	T	20031028	JP 2001-579844	20010501
IN 2002CN01776	A	20050211	IN 2002-CN1776	20021029
US 20030207797	A1	20031106	US 2003-436341	20030512
US 6872701	B2	20050329		

US 20040087494	A1	20040506	US 2003-601847	20030623
US 6903070	B2	20050607		
US 20040063916	A1	20040401	US 2003-669778	20030924
US 6887976	B2	20050503		
US 20040229775	A1	20041118	US 2004-877751	20040625
US 6906031	B2	20050614		
US 20050026820	A1	20050203	US 2004-930585	20040831
US 7026288	B2	20060411		
US 20050032676	A1	20050210	US 2004-931122	20040831
US 7067483	B2	20060627		
US 20050164916	A1	20050728	US 2005-37934	20050118
US 7008923	B2	20060307		
US 20050159344	A1	20050721	US 2005-80130	20050315
US 7157554	B2	20070102		
US 20050164919	A1	20050728	US 2005-83370	20050318
US 7074760	B2	20060711		
US 20060063706	A1	20060323	US 2005-265570	20051102
US 7208471	B2	20070424		
US 20060194716	A1	20060831	US 2006-410549	20060425
US 7244705	B2	20070717		
US 20060194717	A1	20060831	US 2006-410597	20060425
US 20070049519	A1	20070301	US 2006-584908	20061023
US 7351691	B2	20080401		
US 20070042942	A1	20070222	US 2006-589614	20061030
US 7265086	B2	20070904		
JP 2007045842	A	20070222	JP 2006-304562	20061109

PRIORITY APPLN. INFO.:

US 2000-201178P	P	20000502
US 2000-213146P	P	20000622
US 2000-213410P	P	20000622
US 2000-213415P	P	20000622
US 2000-213417P	P	20000622
US 2000-213428P	P	20000622
US 2000-226727P	P	20000818
JP 2002-504283	A3	20010501
US 2001-846893	A1	20010501
US 2001-847041	A1	20010501
US 2001-847042	A1	20010501
US 2001-847052	A1	20010501
WO 2001-US14000	W	20010501
US 2003-601847	A1	20030623
US 2003-669778	A1	20030924
US 2004-877751	A1	20040625
US 2004-931122	A1	20040831
US 2005-37934	A1	20050118
US 2005-80130	A1	20050315
US 2005-83370	A1	20050318
US 2005-265570	A1	20051102

OTHER SOURCE(S): MARPAT 135:362574

L2 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:370467 CAPLUS <<LOGINID::20080616>>
 DOCUMENT NUMBER: 133:9039
 TITLE: Preparation and evaluation of new eye-drops containing
 a combination of ciprofloxacin and dexamethasone
 AUTHOR(S): Doshi, H. A.; Bhalla, H. L.
 CORPORATE SOURCE: B.V. Patel PERD Centre, Ahmedabad, 380 054, India
 SOURCE: Indian Drugs (2000), 37(4), 190-195
 CODEN: INDRBA; ISSN: 0019-462X

PUBLISHER: Indian Drug Manufacturers' Association
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:228182 CAPLUS <<LOGINID::20080616>>
DOCUMENT NUMBER: 124:337227
ORIGINAL REFERENCE NO.: 124:62469a,62472a
TITLE: Preliminary interpretive criteria for disk diffusion
susceptibility testing of SCH 27899, a compound in the
everninomicin class of antimicrobial agents
AUTHOR(S): Cormican, Martin G.; Marshall, Steven A.; Jones,
Ronald N.
CORPORATE SOURCE: College of Medicine, University of Iowa, Iowa City,
IA, USA
SOURCE: Diagnostic Microbiology and Infectious Disease (
1995), 23(4), 157-60
CODEN: DMIDDZ; ISSN: 0732-8893
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 15:12:19 ON 16 JUN 2008)

FILE 'CAPLUS' ENTERED AT 15:12:35 ON 16 JUN 2008

L1 44 S CYCLODEXTRIN AND BACTERIA? AND (INFECT? OR INVASI? OR DISEASE
L2 8 S L1 AND HYDROXYPROPYL
L3 1 S L2 AND LISTERI?
L4 2 S L1 AND LISTERI?

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.64	31.85

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:16:01 ON 16 JUN 2008